Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
2.
Global Advances in Health and Medicine ; 11:47, 2022.
Article in English | EMBASE | ID: covidwho-1916546

ABSTRACT

Methods: The survey was designed by an international team, translated and adapted to simplified Chinese, including 132 kinds of traditional Chinese medicine (TCM) preparation recommended by guidelines. It was distributed and collected from February to May 2021, with data analysed by WPS spreadsheet and wjx.cn. Descriptive statistics were used to describe demographics and clinical characteristics, diagnosis, treatments, preventative behaviours and interventions, and their associated outcomes. Results: The survey was accessed 503 times with 341 (67.8%) completions covering 23 provinces and four municipalities in China. Most (282/341, 82.7%) respondents reported no symptoms during the pandemic and the majority (290/341, 85.0%) reported having a SARS-CoV-2 PCR test at some point. Forty-five (13.2%) reported having a respiratory infection, among which 19 (42.2%) took one or more categories of modern medicine, e.g. painkillers, antibiotics;16 (35.6%) used TCM interventions(s);while seven respondents combined TCM with modern medicine. All respondents reported using at least one behavioural or medical approach to prevention, with 22.3% taking TCM and 5.3% taking modern medicines. No respondents reported having a critical condition related to COVID-19. Background: We aimed to investigate use of infection control behaviours, preventative and therapeutic interventions, and outcomes among respondents to an online survey during the COVID-19 pandemic in China. Conclusion: We found evidence of widespread use of infection control behaviours, modern medicines and TCM for treatment and prevention of COVID-19 and other respiratory symptoms. Larger scale studies are warranted, including a more representative sample exploring TCM preparations recommended in clinical guidelines.

3.
European Journal of Integrative Medicine ; 48, 2021.
Article in English | EMBASE | ID: covidwho-1587783

ABSTRACT

Introduction: Chinese patent medicine (CPM) is an indispensable part of traditional Chinese medicine. Coronavirus Disease 2019 (COVID-19) manifests is an acute respiratory infectious disease. This systematic review aimed to evaluate the therapeutic effects and safety of oral CPM for COVID-19. Methods: We included randomized controlled trials (RCTs) that tested oral CPM for the treatment of COVID-19 identified from publications in CNKI, Wanfang, VIP, Web of Science, SinoMed, PubMed, Embase, BioRxiv, MedRxiv and arXiv before November 2nd, 2020. The risk of bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed using the online GRADEpro tool. Results: Seven RCTs including 1079 participants were identified. The overall bias was assessed as “some concerns” for all included trials. Oral CPM investigated were: Lianhua Qingwen capsule/granules (连花清瘟胶囊/颗粒, LHQW), Jinhua Qinggan granules (金花清感颗粒, JHQG), Huoxiang Zhengqidripping pills (藿香正气滴丸, HXZQ), Toujie Quwen granules (透解祛瘟颗粒, TJQW) and Lianhua Qingke granules (连花清咳颗粒, LHQK). Compared with conventional western therapy alone for people with COVID-19: regarding the main outcomes, the results showed that oral CPM combined with conventional western therapy improved cure rate (RR = 1.20, 95% CI 1.04 to 1.38, involving LHQW and TJQW), reduced aggravation rate (RR = 0.50, 95% CI 0.29 to 0.85, involving LHQW, JHQG, LHQK and TJQW);with regard to additional outcomes, the results showed that add-on oral CPM shortened the duration of fever, cough and fatigue, improved the recovery rate of cough and fatigue, and increased the improvement and recovery rate of chest CT manifestations. There were some differences in therapeutic effects among various CPMs for the same COVID-19 outcome. The use of TJQW and LHQG appeared not to increase the risk of adverse events, but JHQG may cause mild diarrhea. Conclusions: Low-certainty or very low-certainty evidence demonstrated that oral CPM may have add-on potential therapeutic effects for patients with non-serious COVID-19. There are some differences in therapeutic effects between different oral CPMs for the same outcome of COVID-19. The use of TJQW and LHQG probably does not increase the risk of adverse events, but JHQG may cause mild diarrhea in patients. The conclusion of this review needs to be further confirmed by well-designed clinical trials with adequate sample sizes. Keywords: Coronavirus Disease 2019;COVID-19;Chinese patent medicine;Chinese herbal medicine;Systematic review;Meta-analysis

4.
European Journal of Integrative Medicine ; 48, 2021.
Article in English | EMBASE | ID: covidwho-1587782

ABSTRACT

Introduction: Coronavirus Disease 2019 (COVID-19) is an acute respiratory infectious disease. At present, there is no specific and effective therapy for the treatment and prevention of this disease. Traditional Chinese medicine (TCM) has accumulated thousands of years of experience on the use of Chinese herbal medicine (CHM) to prevent and treat infectious diseases. The aim of this study was to present the evidence on the therapeutic effects and safety of Chinese herbal medicine (CHM) used with or without conventional western therapy for COVID-19. Methods: Clinical studies on the therapeutic effects and safety of CHM for COVID-19 were included. We summarized the general characteristics of included studies, evaluated methodological quality of randomized controlled trials (RCTs) using the Cochrane risk of bias tool, analyzed the use of CHM, used Revman 5.4 software to present the risk ratio (RR) or mean difference (MD) and their 95% confidence interval (CI) to estimate the therapeutic effects and safety of CHM. Results: A total of 58 clinical studies were identified including RCTs (17.24%, 10), non-randomized controlled trials (1.72%, 1), retrospective studies with a control group (18.97%, 11), case-series (20.69%, 12) and case-reports (41.38%, 24). Fig.1 shows the flow diagram for the searching and screening of published articles. No RCTs of high methodological quality were identified. The most frequently tested oral Chinese patent medicine, Chinese herbal medicine injection or prescribed herbal decoction were: Lianhua Qingwen granule/capsule, Xuebijing injection and Maxing Shigan Tang. Table 1 lists the CHM used at least twice. In terms of aggravation rate, pooled analyses showed that there were statistical differences between the intervention group and the comparator group (RR 0.42, 95% CI 0.21 to 0.82, six RCTs;RR 0.38, 95% CI 0.23 to 0.64, five retrospective studies with a control group), that is, CHM plus conventional western therapy appeared better than conventional western therapy alone in reducing aggravation rate. In addition, compared with conventional western therapy, CHM plus conventional western therapy had potential advantages in increasing the recovery rate and shortening the duration of fever, cough and fatigue, improving the negative conversion rate of nucleic acid test, and increasing the improvement rate of chest CT manifestations and shortening the time from receiving the treatment to the beginning of chest CT manifestations improvement. For adverse events, pooled data showed that there were no statistical differences between the CHM and the control groups. Conclusion: Current low certainty evidence suggests that there may be a tendency that CHM plus conventional western therapy is superior to conventional western therapy alone. The use of CHM did not increase the risk of adverse events. Keywords: traditional Chinese medicine, Chinese herbal medicine, novel coronavirus pneumonia, coronavirus disease 2019, COVID-19, SARS-CoV-2, review, clinical study

5.
Tropical Cyclone Research and Review ; 10(2):116-123, 2021.
Article in English | Web of Science | ID: covidwho-1324319

ABSTRACT

The unexpectedly outbreak of COVID-19 in early 2020, as a public emergency, has impacted the way of human behavior deeply and widely in today's society, including the countermeasures of typhoon-related disaster risk reduction and preparedness in the Members of Typhoon Committee (TC). This paper briefed the impacts due to COVID-19 pandemic on activities of the Committee in 2020;introduced the countermeasures took in National Hydrological and Meteorological Services (NHMS) of TC Members during typhoon season in 2020 for coping with the crisis caused by COVID-19 pandemic;summarized the innovative strategies and countermeasures for dealing with the crisis of special or emergency public situation for typhoon-related disaster risk prevention, preparedness and reduction in future based on the review and analysis of the experiences from Members and international/regional agencies, and the outcomes from TC Integrated Workshop and Annual Session, including strengthening meteorological and hydrological services and value of preparedness;enhancing multi-sectoral coordination mechanisms;promoting the mobile-based data transmission and information dissemination;and increasing installation of home-based hydro-meteorological monitoring stations. The paper also discussed the impact-based forecasting and the application of big-data and AI technology in typhoon-related disaster risk reduction as two new key areas to be taken into consideration in TC updating Strategic Plan 2022-2026. (C) 2021 The Shanghai Typhoon Institute of China Meteorological Administration. Publishing services by Elsevier B.V. on behalf of KeAi Communication Co. Ltd.

6.
Global Advances in Health and Medicine ; 10:24-25, 2021.
Article in English | EMBASE | ID: covidwho-1234517

ABSTRACT

Objective: To present the evidence of the effectiveness and safety of Chinese herbal medicine (CHM) used with or without conventional western therapy on COVID-19. Methods: Clinical studies on effectiveness and safety of CHM for COVID-19 were included. We summarized general characteristics of included studies, evaluated methodological quality of randomized controlled trials (RCTs), analyzed the use of CHM, estimated the effectiveness and safety of CHM. Results: A total of 58 clinical studies were identified including RCTs (17.24%, 10), non-randomized controlled trials (1.72%, 1), retrospective studies with a control group (18.97%, 11), case-series (20.69%, 12) and case-reports (41.38%, 24). No high methodological quality RCTs were identified. The most frequently tested Chinese patent medicine, Chinese herbal medicine injection or prescribed herbal decoction were: Lianhua Qingwen granule/capsule, Xuebijing injection and Maxing Shigan Tang. In terms of aggravation rate, pooled analyses showed that there had statistical differences between the intervention group and the comparator group (RR 0.42, 95% CI 0.21 to 0.82, 6 RCTs;RR 0.37, 95% CI 0.22 to 0.64, 4 retrospective studies with control group), that is, CHM plus conventional western therapy appeared better than conventional western therapy in reducing aggravation rate. In addition, compared with conventional western therapy, CHM plus conventional western therapy had potential advantages in increasing the resolution rate and shortening the duration of fever, cough and fatigue, improving the negative conversion rate of nucleic acid test, and increasing the number of patients with inflammatory disappearance or shortening the time from receiving treatment to beginning of inflammation disappearance. For adverse events, pooled data showed that there was no statistical difference between the CHM and the control groups. Conclusion: Current low certainty evidence suggests that there may be a tendency that CHM plus conventional western therapy is superior to conventional western therapy alone. The use of CHM did not increase the risk of adverse events.

SELECTION OF CITATIONS
SEARCH DETAIL